gefitinib has been researched along with benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone) | Trials (benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone) | Recent Studies (post-2010) (benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 1,897 | 0 | 411 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lindner, H; Loeffler-Ragg, J; Lukas, P; Sarg, B; Skvortsov, S; Skvortsova, I; Tabernero, J; Zwierzina, H | 1 |
1 other study(ies) available for gefitinib and benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
| Article | Year |
|---|---|
Irreversible pan-ErbB tyrosine kinase inhibitor CI-1033 induces caspase-independent apoptosis in colorectal cancer DiFi cell line.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Apoptosis Inducing Factor; Caco-2 Cells; Caspase 3; Caspases; Cathepsin D; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Gefitinib; Genes, Tumor Suppressor; Humans; Morpholines; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; Serpins | 2005 |